Global Antibiotics Market 2020-2030

Bonafide Trust 26-08-2020 182 Pages Figures : 93 Tables : 42
Region : Global Category : Lifescience Pharmaceutical

Request new version

Request for updated version of the report at the same price

Order Now

Report Description
Table of Contents
List of Figure Tables

Global antibiotics market will reach $63.99 billion by 2030, growing by 3.5% annually over 2020-2030 driven by rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic. Highlighted with 86 tables and 93 figures, this 182-page report “Global Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Region. Based on Drug Class, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cephalosporin • Penicillin • Macrolides • Fluoroquinolones • Quinolones • Monobactam • Aminoglycosides • Carbapenem • Other Drug Classes Based on Action Mechanism, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cell Wall Synthesis Inhibitors • Mycolic Acid Inhibitors • RNA Synthesis Inhibitors • DNA Synthesis Inhibitors • Protein Synthesis Inhibitors • Other Mechanisms Based on Drug Origin, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Natural Antibiotics • Semi-synthetic Antibiotics • Synthetic Antibiotics Based on Activity Spectrum, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Broad-spectrum Antibiotics • Narrow-spectrum Antibiotics Based on Route of Administration, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Intravenous Administration • Other Administration Routes Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Brand Antibiotics • Generic Antibiotics Geographically, the following regions together with the listed national/local markets are fully investigated: • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) • North America (U.S., Canada, and Mexico) • South America (Brazil, Chile, Argentina, Rest of South America) • RoW (Saudi Arabia, UAE, South Africa) For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in global antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Astellas Pharma AstraZeneca Plc Bayer AG Bristol Myers Squibb Company Cipla Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. GlaxoSmithKline plc. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) Mayne Pharma Group Ltd. MELINTA THERAPEUTICS, INC. Merck KGaA Novartis AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 10

1.1 Industry Definition and Research Scope 10

1.1.1 Industry Definition 10

1.1.2 Research Scope 11

1.2 Research Methodology 14

1.2.1 Overview of Market Research Methodology 14

1.2.2 Market Assumption 15

1.2.3 Secondary Data 15

1.2.4 Primary Data 15

1.2.5 Data Filtration and Model Design 17

1.2.6 Market Size/Share Estimation 18

1.2.7 Research Limitations 19

1.3 Executive Summary 20

2 Market Overview and Dynamics 23

2.1 Market Size and Forecast 23

2.1.1 Impact of COVID-19 on the Market 24

2.2 Major Growth Drivers 26

2.3 Market Restraints and Challenges 30

2.4 Emerging Opportunities and Market Trends 33

2.5 Porter’s Fiver Forces Analysis 37

3 Segmentation of Global Market by Drug Class 41

3.1 Market Overview by Drug Class 41

3.2 Cephalosporin 43

3.3 Penicillin 44

3.4 Macrolides 45

3.5 Fluoroquinolones 46

3.6 Quinolones 47

3.7 Monobactam 48

3.8 Aminoglycosides 49

3.9 Carbapenem 50

3.10 Other Drug Classes 51

4 Segmentation of Global Market by Action Mechanism 52

4.1 Market Overview by Action Mechanism 52

4.2 Cell Wall Synthesis Inhibitors 54

4.3 Mycolic Acid Inhibitors 55

4.4 RNA Synthesis Inhibitors 56

4.5 DNA Synthesis Inhibitors 57

4.6 Protein Synthesis Inhibitors 58

4.7 Other Mechanisms 59

5 Segmentation of Global Market by Drug Origin 60

5.1 Market Overview by Drug Origin 60

5.2 Natural Antibiotics 62

5.3 Semi-synthetic Antibiotics 63

5.4 Synthetic Antibiotics 64

6 Segmentation of Global Market by Activity Spectrum 65

6.1 Market Overview by Activity Spectrum 65

6.2 Broad-spectrum Antibiotics 67

6.3 Narrow-spectrum Antibiotics 68

7 Segmentation of Global Market by Route of Administration 69

7.1 Market Overview by Route of Administration 69

7.2 Oral Administration 71

7.3 Intravenous Administration 72

7.4 Other Administration Routes 73

8 Segmentation of Global Market by Drug Type 74

8.1 Market Overview by Drug Type 74

8.2 Brand Antibiotics 76

8.3 Generic Antibiotics 77

9 Segmentation of Global Market by Region 78

9.1 Geographic Market Overview 2019-2030 78

9.2 North America Market 2019-2030 by Country 84

9.2.1 Overview of North America Market 84

9.2.2 U.S. 88

9.2.3 Canada 92

9.2.4 Mexico 94

9.3 European Market 2019-2030 by Country 96

9.3.1 Overview of European Market 96

9.3.2 Germany 100

9.3.3 UK 102

9.3.4 France 104

9.3.5 Spain 106

9.3.6 Italy 108

9.3.7 Russia 110

9.3.8 Rest of European Market 112

9.4 Asia-Pacific Market 2019-2030 by Country 114

9.4.1 Overview of Asia-Pacific Market 114

9.4.2 Japan 118

9.4.3 China 121

9.4.4 Australia 123

9.4.5 India 125

9.4.6 South Korea 127

9.4.7 Rest of APAC Region 129

9.5 South America Market 2019-2030 by Country 131

9.5.1 Argentina 134

9.5.2 Brazil 136

9.5.3 Chile 138

9.5.4 Rest of South America Market 140

9.6 MEA Market 2019-2030 by Country 141

9.6.1 UAE 144

9.6.2 Saudi Arabia 146

9.6.3 South Africa 148

9.6.4 Other National Markets 150

10 Competitive Landscape 151

10.1 Overview of Key Vendors 151

10.2 New Product Launch, Partnership, Investment, and M&A 155

10.3 Company Profiles 156

Abbott Laboratories 156

Astellas Pharma 158

AstraZeneca Plc 159

Bayer AG 160

Bristol Myers Squibb Company 161

Cipla Inc. 162

Dr. Reddy’s Laboratories Ltd. 163

Eli Lilly and Company 164

F. Hoffmann-La Roche Ltd. 165

Gilead Sciences, Inc. 166

GlaxoSmithKline plc. 167

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 168

Mayne Pharma Group Ltd. 169

MELINTA THERAPEUTICS, INC. 170

Merck KGaA 171

Novartis AG 172

Pfizer Inc. 173

Sanofi 174

Sun Pharmaceutical Industries Ltd. 175

11 Investing in Global Market: Risk Assessment and Management 176

11.1 Risk Evaluation of Global Market 176

11.2 Critical Success Factors (CSFs) 179

Related Reports and Products 182

Figure 1. Research Method Flow Chart 14
Figure 2. Breakdown of Primary Research 16
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 18
Figure 4. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 20
Figure 5. Global Antibiotics Market, 2019-2030, $ mn 23
Figure 6. Impact of COVID-19 on Business 24
Figure 7. Primary Drivers and Impact Factors of Global Antibiotics Market 26
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 29
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 29
Figure 10. Primary Restraints and Impact Factors of Global Antibiotics Market 30
Figure 11. Investment Opportunity Analysis 34
Figure 12. Porter’s Fiver Forces Analysis of Global Antibiotics Market 37
Figure 13. Breakdown of Global Antibiotics Market by Drug Class, 2019-2030, % of Revenue 42
Figure 14. Global Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%) 42
Figure 15. Global Antibiotics Market: Cephalosporin, 2019-2030, $ mn 43
Figure 16. Global Antibiotics Market: Penicillin, 2019-2030, $ mn 44
Figure 17. Global Antibiotics Market: Macrolides, 2019-2030, $ mn 45
Figure 18. Global Antibiotics Market: Fluoroquinolones, 2019-2030, $ mn 46
Figure 19. Global Antibiotics Market: Quinolones, 2019-2030, $ mn 47
Figure 20. Global Antibiotics Market: Monobactam, 2019-2030, $ mn 48
Figure 21. Global Antibiotics Market: Aminoglycosides, 2019-2030, $ mn 49
Figure 22. Global Antibiotics Market: Carbapenem, 2019-2030, $ mn 50
Figure 23. Global Antibiotics Market: Other Drug Classes, 2019-2030, $ mn 51
Figure 24. Breakdown of Global Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue 53
Figure 25. Global Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%) 53
Figure 26. Global Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn 54
Figure 27. Global Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn 55
Figure 28. Global Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn 56
Figure 29. Global Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn 57
Figure 30. Global Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn 58
Figure 31. Global Antibiotics Market: Other Mechanisms, 2019-2030, $ mn 59
Figure 32. Breakdown of Global Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue 61
Figure 33. Global Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%) 61
Figure 34. Global Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn 62
Figure 35. Global Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn 63
Figure 36. Global Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn 64
Figure 37. Breakdown of Global Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue 66
Figure 38. Global Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%) 66
Figure 39. Global Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn 67
Figure 40. Global Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn 68
Figure 41. Breakdown of Global Antibiotics Market by Route of Administration, 2019-2030, % of Revenue 70
Figure 42. Global Addressable Market Cap in 2020-2030 by Route of Administration, Value ($ mn) and Share (%) 70
Figure 43. Global Antibiotics Market: Oral Administration, 2019-2030, $ mn 71
Figure 44. Global Antibiotics Market: Intravenous Administration, 2019-2030, $ mn 72
Figure 45. Global Antibiotics Market: Other Administration Routes, 2019-2030, $ mn 73
Figure 46. Breakdown of Global Antibiotics Market by Drug Type, 2019-2030, % of Revenue 74
Figure 47. Global Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%) 75
Figure 48. Global Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn 76
Figure 49. Global Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn 77
Figure 50. Global Market Snapshot by Region 78
Figure 51. Geographic Spread of Worldwide Antibiotics Market, 2019-2030, % of Sales Revenue 79
Figure 52. Global Addressable Market Cap in 2020-2030 by Region, Value ($ bn) and Share (%) 80
Figure 53. Health Spending as a Share of GDP by Country, 2015 and 2030 82
Figure 54. North American Antibiotics Market, 2019-2030, $ bn 85
Figure 55. Breakdown of North America Antibiotics Market by Country, 2019 and 2030, % of Revenue 86
Figure 56. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 87
Figure 57. U.S. Antibiotics Market, 2019-2030, $ bn 89
Figure 58. Rising Incidence of Infectious Disease in U.S. 89
Figure 59. Canada Antibiotics Market, 2019-2030, $ bn 92
Figure 60. Antibiotics Market in Mexico, 2015-2030, $ bn 94
Figure 61. European Antibiotics Market, 2019-2030, $ bn 97
Figure 62. Breakdown of European Antibiotics Market by Country, 2019 and 2030, % of Revenue 98
Figure 63. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 99
Figure 64. Antibiotics Market in Germany, 2019-2030, $ bn 100
Figure 65. Antibiotics Market in UK, 2019-2030, $ bn 102
Figure 66. Antibiotics Market in France, 2019-2030, $ bn 104
Figure 67. Antibiotics Market in Spain, 2019-2030, $ bn 106
Figure 68. Antibiotics Market in Italy, 2019-2030, $ bn 108
Figure 69. Antibiotics Market in Russia, 2019-2030, $ bn 110
Figure 70. Antibiotics Market in Rest of Europe, 2019-2030, $ bn 112
Figure 71. Asia-Pacific Antibiotics Market, 2019-2030, $ bn 115
Figure 72. Breakdown of APAC Antibiotics Market by Country, 2019 and 2030, % of Revenue 115
Figure 73. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 117
Figure 74. Antibiotics Market in Japan, 2019-2030, $ bn 119
Figure 75. Antibiotics Market in China, 2019-2030, $ bn 121
Figure 76. Antibiotics Market in Australia, 2019-2030, $ bn 123
Figure 77. Antibiotics Market in India, 2019-2030, $ bn 125
Figure 78. Antibiotics Market in South Korea, 2019-2030, $ bn 127
Figure 79. Antibiotics Market in Rest of APAC, 2019-2030, $ bn 129
Figure 80. South America Antibiotics Market, 2019-2030, $ bn 132
Figure 81. Breakdown of South America Antibiotics Market by Country, 2019 and 2030, % of Revenue 132
Figure 82. Contribution to South America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 133
Figure 83. Antibiotics Market in Argentina, 2019-2030, $ bn 134
Figure 84. Antibiotics Market in Brazil, 2019-2030, $ bn 136
Figure 85. Antibiotics Market in Chile, 2019-2030, $ bn 138
Figure 86. Antibiotics Market in Rest of South America, 2019-2030, $ bn 140
Figure 87. Antibiotics Market in Middle East and Africa (MEA), 2019-2030, $ bn 142
Figure 88. Breakdown of MEA Antibiotics Market by Country, 2019 and 2030, % of Revenue 142
Figure 89. Contribution to MEA 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 143
Figure 90. Antibiotics Market in UAE, 2019-2030, $ bn 144
Figure 91. Antibiotics Market in Saudi Arabia, 2019-2030, $ bn 146
Figure 92. Antibiotics Market in South Africa, 2019-2030, $ bn 148
Figure 93. Growth Stage of Global Antibiotics Industry over the Forecast Period 151

Table 1. Snapshot of Europe Digital Biomarkers Market, 2019-2030 18
Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples 22
Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030 30
Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year 31
Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year 31
Table 6. Current Challenges of Digital Biomarkers in Medical Settings 34
Table 7. Main Product Trends and Market Opportunities in Europe Digital Biomarkers Market 37
Table 8. Europe Digital Biomarkers Market by System Component, 2019-2030, $ mn 45
Table 9. Europe Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, $ mn 48
Table 10. Europe Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 55
Table 11. Europe Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, $ mn 59
Table 12. Europe Digital Biomarkers Market by Application, 2019-2030, $ mn 70
Table 13. Europe Digital Biomarkers Market by Development Status, 2019-2030, $ mn 78
Table 14. Europe Digital Biomarkers Market by End User, 2019-2030, $ mn 83
Table 15. Europe Digital Biomarkers Market by Country, 2019-2030, $ mn 90
Table 16. Germany Digital Biomarkers Market by System Component, 2019-2030, $ mn 92
Table 17. Germany Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 92
Table 18. Germany Digital Biomarkers Market by End User, 2019-2030, $ mn 92
Table 19. UK Digital Biomarkers Market by System Component, 2019-2030, $ mn 94
Table 20. UK Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 94
Table 21. UK Digital Biomarkers Market by End User, 2019-2030, $ mn 94
Table 22. France Digital Biomarkers Market by System Component, 2019-2030, $ mn 96
Table 23. France Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 96
Table 24. France Digital Biomarkers Market by End User, 2019-2030, $ mn 96
Table 25. Netherlands Digital Biomarkers Market by System Component, 2019-2030, $ mn 98
Table 26. Netherlands Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 98
Table 27. Netherlands Digital Biomarkers Market by End User, 2019-2030, $ mn 98
Table 28. Italy Digital Biomarkers Market by System Component, 2019-2030, $ mn 100
Table 29. Italy Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 100
Table 30. Italy Digital Biomarkers Market by End User, 2019-2030, $ mn 100
Table 31. Russia Digital Biomarkers Market by System Component, 2019-2030, $ mn 102
Table 32. Russia Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 102
Table 33. Russia Digital Biomarkers Market by End User, 2019-2030, $ mn 102
Table 34. Digital Biomarkers Market in Rest of Europe by Country, 2019-2030, $ mn 104
Table 35. Breakdown of Europe Market by Key Vendor, 2019, % 107
Table 36. Actigraph LLC: Company Snapshot 110
Table 37. Actigraph LLC: Business Segmentation 110
Table 38. Actigraph LLC: Product Portfolio 111
Table 39. Actigraph LLC: Revenue, 2016-2018, $ mn 111
Table 40. Actigraph LLC: Recent Developments 111
Table 41. Risk Evaluation for Investing in Europe Market, 2019-2030 140
Table 42. Critical Success Factors and Key Takeaways 143

Interested in this report?
Get your FREE sample!

Safe and Secure SSl Encryption

Licensing options

3600
USD

Single User License
Site License
Global User License

How client has rates us?

Requirement Gathering & Methodology

Data Collection Techniques

Our Research Team & Data Sourcing

Data Science & Analytical Tools

Data Visualization & Presentation Skills

Project/ Report Delivery & After Sales Services

Testimonial

READY TO MIX MARKET HAS HELPED US TO UNDERSTAND PRODUCT, PRICE & VARIENTS OF ALL THE COMPETITION INCLUDING SMALL STARTUPS/REGIONAL PLAYERS.

PRODUCT DEVELOPMENT MANAGER

CEO

Vivek Arora

BEING A STARTUP WE WERE NOT AWARE ABOUT E-COMMERCE LOGISTICS, THE REPORT HAS RESOLVED ALL OUR QUERIES. THE TEAM HAVE IN DEPTH KNOWLEDGE OF LOGISTICS. REMARKABLE!!

EXECUTIVE DIRECTOR

Rahul Roy

THE REPORT WAS GOOD FOR OUR STUDY, I WOULD STRONGLY RECOMMEND BONAFIDE RESEARCH. A VERY CUSTOMER CENTRIC AND APPROACHABLE TEAM.

SALES DIRECTOR

Arjun Prasad

THE COMPANY WHICH THOROUGHLY UNDERSTANDS INDIAN CONSUMER AND INDIAN MARKET. WE ARE REALLY HAPPY TO WORK WITH BONAFIDE RESEARCH

MARKETING MANAGER

President

Manish Verma

Bonafide Research did an outstanding work on Global Hand Sanitizer project. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

MARKETING DIRECTOR

Gautam Saxena

The study done by Bonafide Research was customized with all our needs. We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done.

PRODUCT MANAGER

Tom Stone

I’m glad I decided to work with you. Thankful to the team for the amazing coordination, it was indeed a good experience, would definitely recommend and come back for future prospects.

Associate Director

Mark Wood

Global Antibiotics Market 2020-2030

Global Antibiotics Market 2020-2030